An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma

Trial Profile

An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Abemaciclib (Primary) ; Galunisertib (Primary) ; LY 3023414 (Primary) ; Capecitabine; Gemcitabine
  • Indications Adenocarcinoma
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 09 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 01 Aug 2017 Planned number of patients changed from 256 to 231.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top